Literature DB >> 1963844

Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers.

J Galitzky1, D Rivière, M A Tran, J L Montastruc, M Berlan.   

Abstract

The effects of 14 days of treatment with the alpha 2-adrenoceptor antagonist yohimbine on cardiovascular parameters (blood pressure and heart rate), plasma catecholamines, insulin and non-esterified fatty acids (NEFA), and the number of alpha 2-adrenoceptors on platelets have been evaluated. The treatment increased plasma noradrenaline but not adrenaline and did not change the other cardiovascular, metabolic or routine blood parameters. It caused a decrease in the velocity of adrenaline-induced platelet aggregation, although [3H]-yohimbine binding to platelets remained unchanged. Acute administration of yohimbine before the experiment led to a significant increase in plasma noradrenaline and NEFA levels. After the 15 day treatment, acute administration of the same dose of yohimbine had less effect on plasma NEFA and there was no significant change in plasma noradrenaline. The acute lipid-mobilizing effect of yohimbine in healthy volunteers persisted after the 14 days of treatment with no change in other parameters. The prolonged alpha 2-adrenoceptor blockade with yohimbine did not induce any change in platelet alpha 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1963844     DOI: 10.1007/bf00280934

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Mechanism of the lipid-mobilizing effect of alpha-2 adrenergic antagonists in the dog.

Authors:  M Taouis; M Berlan; P Montastruc; M Lafontan
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

2.  Yohimbine increases human salivary secretion.

Authors:  E Chatelut; Y Rispail; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

3.  Beta-adrenoceptor changes in blood lymphocytes and altered drug responsiveness.

Authors:  O E Brodde; X L Wang
Journal:  Ann Clin Res       Date:  1988

4.  Heterogeneous distribution of beta and alpha-2 adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences.

Authors:  P Mauriege; J Galitzky; M Berlan; M Lafontan
Journal:  Eur J Clin Invest       Date:  1987-04       Impact factor: 4.686

5.  Subtype-selective up-regulation of human saphenous vein beta 2-adrenoceptors by chronic beta-adrenoceptor antagonist treatment.

Authors:  O E Brodde; H R Zerkowski; N Doetsch; M Khamssi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

6.  Yohimbine increases cerebrospinal fluid and plasma norepinephrine but not arginine vasopressin in humans.

Authors:  E R Peskind; R C Veith; D M Dorsa; G Gumbrecht; M A Raskind
Journal:  Neuroendocrinology       Date:  1989-09       Impact factor: 4.914

7.  The pharmacokinetics of yohimbine in man.

Authors:  J A Owen; S L Nakatsu; J Fenemore; M Condra; D H Surridge; A Morales
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Identification of alpha 2-adrenergic receptors in human fat cell membranes by [3H]chlonidine binding.

Authors:  M Berlan; M Lafontan
Journal:  Eur J Pharmacol       Date:  1980-10-31       Impact factor: 4.432

9.  Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol.

Authors:  R D Aarons; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

10.  Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans.

Authors:  M R Goldberg; A S Hollister; D Robertson
Journal:  Hypertension       Date:  1983 Sep-Oct       Impact factor: 10.190

View more
  5 in total

1.  Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants.

Authors:  H Bagheri; L Schmitt; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

Review 2.  [Therapy for organic erectile dysfunction].

Authors:  A J Becker; M Mayer; C G Stief
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

3.  Effect of a 7-day treatment with idazoxan and its 2-methoxy derivative RX 821002 [correction of RX 821001] on alpha 2-adrenoceptors and non-adrenoceptor idazoxan binding sites in rabbits.

Authors:  M Portillo; M Reverte; D Langin; J M Senard; M A Tran; M Berlan; J L Montastruc
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

4.  The effect of yohimbine on sympathetic responsiveness in essential hypertension.

Authors:  C Damase-Michel; M A Tran; M E Llau; F Chollet; J M Senard; B Guiraud-Chaumeil; J L Montastruc; P Montastruc
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Performance, blood profile and gut morphometry of broiler chickens fed diets supplemented with Yohimbe (Pausynistalia yohimbe) and Larvacide.

Authors:  O V Obajuluwa; K A Sanwo; L T Egbeyale; A O Fafiolu
Journal:  Vet Anim Sci       Date:  2020-06-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.